A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination with Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment

Renal cell carcinoma (RCC)

1. Progression-free survival as assessed by Independent Review Facility (IRF), 2. Overall survival

1. Progression-free survival as assessed by investigators, 2. Investigator- and IRF-assessed objective response rate, 3. Investigator- and IRF-assessed duration of objective response, 4. Incidence and severity of adverse events, with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0, 5. Change from baseline in targeted vital signs, 6. Change from baseline in targeted clinical laboratory test results, 7. Atezolizumab concentrations at specified timepoints (for atezolizumab + cabozantinib arm), 8. Cabozantinib concentrations at specified timepoints, 9. Prevalence of anti-drug antibodies (ADAs) to atezolizumab at baseline and incidence of ADAs to atezolizumab during the study (for atezolizumab+ cabozantinib arm)

No related papers found yet.

Papers published before 2008-02-04 may not appear yet. Historical indexing is in progress.

Germany, Poland